MASI vs. LIVN, CNMD, INMD, NTUS, BLFS, STE, BAX, HOLX, PODD, and TFX
Should you be buying Masimo stock or one of its competitors? The main competitors of Masimo include LivaNova (LIVN), CONMED (CNMD), InMode (INMD), Natus Medical (NTUS), BioLife Solutions (BLFS), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), and Teleflex (TFX). These companies are all part of the "medical" sector.
LivaNova (NASDAQ:LIVN) and Masimo (NASDAQ:MASI) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
97.6% of LivaNova shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 0.3% of LivaNova shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Masimo received 73 more outperform votes than LivaNova when rated by MarketBeat users. However, 68.78% of users gave LivaNova an outperform vote while only 63.84% of users gave Masimo an outperform vote.
Masimo has a net margin of 4.01% compared to Masimo's net margin of -2.68%. Masimo's return on equity of 13.59% beat LivaNova's return on equity.
LivaNova has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Masimo has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500.
In the previous week, Masimo had 16 more articles in the media than LivaNova. MarketBeat recorded 19 mentions for Masimo and 3 mentions for LivaNova. Masimo's average media sentiment score of 1.74 beat LivaNova's score of 0.26 indicating that LivaNova is being referred to more favorably in the media.
LivaNova currently has a consensus price target of $66.20, suggesting a potential upside of 8.40%. Masimo has a consensus price target of $138.71, suggesting a potential upside of 11.42%. Given LivaNova's stronger consensus rating and higher possible upside, analysts plainly believe Masimo is more favorable than LivaNova.
Masimo has higher revenue and earnings than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.
Summary
Masimo beats LivaNova on 13 of the 18 factors compared between the two stocks.
Get Masimo News Delivered to You Automatically
Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
